Profile
Sector:
HealthcareCountry:
United StatesIPO:
29 October 2021Website:
http://www.biofrontera.us.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
BFRI Latest News
WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp.
Biofrontera Inc. (NASDAQ: BFRI) Q1 2024 Earnings Conference Call will take place on May 16, 2024 at 10:00 AM ET. Company representatives include Andrew Barwicki, Hermann Luebbert, and Fred Leffler. Conference call participants include Jonathan Aschoff, Bruce Jackson, and others. Thank you for joining the Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call. All participants are currently in listen-only mode.
Biofrontera Inc., a biopharmaceutical company focused on dermatological products, will release its financial results for the quarter ending March 29, 2024 on May 15, 2024 after the market closes. A conference call will be held on May 16 at 10:00am Eastern Time.
After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Biofrontera Inc. (NASDAQ:BFRI ) Q3 2023 Earnings Conference Call November 10, 2023 10:00 AM ET Company Participants Tirth Patel - IR Hermann Luebbert - Chairman, CEO and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded.
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biofrontera Inc. (NASDAQ:BFRI ) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good morning everyone and welcome to the Biofrontera Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please also note today's event is being recorded.
Biofrontera Inc. (BFRI) came out with a quarterly loss of $6.14 per share versus the Zacks Consensus Estimate of a loss of $5.14. This compares to loss of $8.80 per share a year ago.
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago.
What type of business is Biofrontera?
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
What sector is Biofrontera in?
Biofrontera is in the Healthcare sector
What industry is Biofrontera in?
Biofrontera is in the Drug Manufacturers - Specialty & Generic industry
What country is Biofrontera from?
Biofrontera is headquartered in United States
When did Biofrontera go public?
Biofrontera initial public offering (IPO) was on 29 October 2021
What is Biofrontera website?
https://www.biofrontera.us.com
Is Biofrontera in the S&P 500?
No, Biofrontera is not included in the S&P 500 index
Is Biofrontera in the NASDAQ 100?
No, Biofrontera is not included in the NASDAQ 100 index
Is Biofrontera in the Dow Jones?
No, Biofrontera is not included in the Dow Jones index
When does Biofrontera report earnings?
Next earnings report date is not announced yet